Novel CDK2 Inhibitor INCB123667 Shows Promise in Ovarian Cancer
The CDK2 inhibitor INCB123667 showed positive efficacy and safety signals in platinum-resistant/refractory ovarian cancer.
Related Articles
Q-TWiST Analysis Assesses Progression/Toxicity of Belzutifan Vs Everolimus in ccRCC
Results from a Q-TWiST analysis of the LITESPARK-005 trial showed a trend favoring belzutifan over everolimus for patients with clear cell RCC.
Cancer misinformation on social media
CA: A Cancer Journal for Clinicians is ACS’ flagship clinical oncology journal publishing information about the prevention, early detection, and treatment of cancer.
Healio Disruptive Innovators Awards 2024
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Sun Protection
No single method of sun protection can safeguard you perfectly. A complete strategy is the best way to protect yourself against skin cancer.
Healio Disruptive Innovators Awards 2024
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Healio Disruptive Innovators Awards 2024
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Volunteering
Volunteers are important members of the Huntsman Cancer Institute (HCI) team. Volunteer opportinities include comforting patients and their families, working with various HCI services, assisting…
FDA Grants Priority Review to Tab-cel for EBV+ PTLD After Prior Therapies
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
Dissecting JAK2V617F’s double life with and without MPL
In this issue of Blood, Papadopoulos et al delineate myeloproliferative leukemia virus oncogene (MPL)-dependent and -independent phenotypes of JAK2V617F+ m
